KRAS and breast neoplasm: Interestingly, the KRAS-variant predicts ovarian cancer risk in post-menopausal women[22], triple negative breast cancer in pre-menopausal women[22], and aggressive breast tumor biology in post-menopausal women with a history of hormone replacement therapy[26], suggesting that there is a likely impact of estrogen on the tumor-associated function of the KRAS-variant.